Certolizumab pegol, a humanized F(ab’) IgG1 fragment against the TNFα with no ADCC and CDC activities, has consistent efficiency and safety in RA with other TNFα inhibitors (30). This evidence concerns the gene TNF and rheumatoid arthritis.